According to the World Health Organization, cardiovascular disease (CVD) claims an estimated 17 million lives every year . Reducing the number of deaths caused by this disease will require a combination of efforts, from lifestyle choices at the individual and societal levels, to innovations in science and technology. With CVD afflicting more people every year, it is imperative that physicians, clinics, hospitals, and patients have the best tools available for the rapid, accurate diagnoses of CVD. Now, because of the combined efforts of Innovation & Intellectual Property, Pacific Nanoscience, a Portland-based company interested in promoting and developing nanotechnology in the medical field, and The Baker Group, there is a promising new tool for the diagnosis of CVD in development. The Nanomonitor can identify a patient’s level of CVD risk before a cardiac event by taking precise measurements of the CVD biomarker troponin.
Innovation & Intellectual Property maintained the patent portfolio that made the advance in troponin detection possible for seven years while searching for commercial partners interested in taking the technology developed at Portland State University by Dr. Shalini Prasad and her collaborator, Dr. Thomas W. Barrett to market. After years, Innovation & Intellectual Property was able to connect Pacific Nanoscience with Michael Baker, the company’s future CEO. Now Pacific Nanoscience, with the support of The Baker Group, has plans to develop the Nanomonitor into a cost-effective tool for use in hospitals and emergency rooms where it will have the potential to help physicians save millions of lives every year.
"With the Nanomonitor as designed by Pacific Nanoscience, we have the potential to greatly enhance outcomes for cardiac patients," Brenda Edin, a partner at The Baker Group, said.
The early detection of CVD can save lives, money, and unnecessary pain and heartache, and with the Nanomonitor, early detection of CVD will be only a simple, inexpensive test away. With the efforts of Pacific Nanoscience, The Baker Group, and Innovation & Intellectual Property, this life-saving technology may soon be in the hands of health care providers in hospitals and health centers around the world.